LONDON – Astrazeneca plc is pushing personalized medicine and targeted therapies beyond the confines of cancer and into cardiovascular, metabolic and respiratory indications, with plans for a companion diagnostic for a phase III asthma product and a large-scale R&D tie-up with the Montreal Heart Institute to discover genetic markers with which to stratify heart disease and diabetes patients.